| 产品描述: | AZ13705339 是一种高效且具有选择性的 PAK1 抑制剂,对 PAK1 和 pPAK1 的 IC50 分别为 0.33 nM 和 59 nM。AZ13705339 对 PAK1 和 PAK2 具有结合亲和力,Kd 分别为 0.28 nM 和 0.32 nM。AZ13705339 可用于癌症研究。 |
| 靶点: |
PAK2:0.32 nM (Kd);PAK1:0.28 nM (Kd);PAK |
| 体外研究: |
AZ13705339 (1 μM) inhibits αIgM-controlled adhesion and not PMA-induced adhesion in Namalwa cells. AZ13705339 (300 nM, 30 min) prevents Siglec-8 engagement-induced eosinophil death. |
| 体内研究: |
AZ13705339 (100 mg/kg, P.O.) has moderate clearance and oral Cmax of 7.7 μM in rats. |
| 参考文献: |
1. McCoull W, Hennessy EJ, Blades K, et al. Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. ACS Med Chem Lett. 2016;7(12):1118-1123. Published 2016 Sep 14. [Content Brief]
2. Martin F M de Rooij, et al. A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nat Commun. 2022 Apr 19;13(1):2136. [Content Brief]
3. Daniela J Carroll, et al. Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro. Front Immunol. 2021 Oct 11;12:737988. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.588 ml |
7.94 ml |
15.879 ml |
| 5 mM |
0.318 ml |
1.588 ml |
3.176 ml |
| 10 mM |
0.159 ml |
0.794 ml |
1.588 ml |
| 50 mM |
0.032 ml |
0.159 ml |
0.318 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |